Yanwei Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yanwei Lu has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Haibo Zhang
Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, China
10 shared publications Ruiqi Liu
Department of Pathology Tongde Hospital of Zhejiang Province Hangzhou Zhejiang China
8 shared publicationsLuanluan Huang
Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China
7 shared publicationsXiaoyan Chen
Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China
7 shared publications- Hailong Sheng
Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, China
4 shared publications Hao Xiong
Cancer Center Department of Radiation Oncology Zhejiang Provincial People's Hospital (Affiliated People's Hospital) Hangzhou Medical College Hangzhou Zhejiang China
4 shared publications
Latest Publications
- Open Access
- 18 December 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 338 (Pt 2) , 149734
A KAT7-lncPVT1 positive feedback loop promotes lung cancer carcinogenesis and therapy resistance via H3K14ac/HDGF/PI3K/AKT Axis
- 18 December 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 338 (Pt 2) , 149734
Open AccessA KAT7-lncPVT1 positive feedback loop promotes lung cancer carcinogenesis and therapy resistance via H3K14ac/HDGF/PI3K/AKT Axis
- Open Access
- 29 September 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (10) , e70478
Lactylation in cancer: Advances and opportunities for treatment resistance
Background: Lactylation, a recently identified post‐translational modification that utilizes lactic acidas a substrate, has emerged as an important regulator of gene expression andprotein function. Since its discovery in 2019, lactylation has beenincreasingly recognized for its roles in cancer biology and treatment response. Main text: Lactylationis strongly associated with tumor progression and malignancy, underscoring itspotential as a therapeutic target. Recent studies also link lactylation tocancer treatment resistance, suggesting that modulating this modification couldenhance therapeutic efficacy. As treatment resistance remains a major clinicalchallenge in oncology, accumulating evidence indicates that dysregulatedlactylation contributes to resistance across chemotherapy, immunotherapy, targeted therapy, and radiotherapy. Preclinical and clinical research has begunto delineate the molecular pathways through which lactylation shapes theseresistance processes, and experimental approaches targeting lactylation arebeing explored to restore therapeutic sensitivity. Conclusion: This review systematically summarizes the mechanisms of lactylation and its roles intreatment resistance, highlighting the interplay between lactylation andtherapeutic response. We discuss current and emerging strategies that targetlactylation, providing a foundation for future therapeutic development aimed atovercoming resistance and improving cancer treatment outcomes. Key points: Lactylation links glycolysis to tumor progression and therapeutic response. Modulating lactylation writers and erasers restores treatment sensitivity. Aberrant lactylation drives resistance tomultiple cancer therapies. Crosstalk with other post‐translational modifications suggests novel combination strategies.
- 29 September 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (10) , e70478
Open AccessLactylation in cancer: Advances and opportunities for treatment resistance
Background: Lactylation, a recently identified post‐translational modification that utilizes lactic acidas a substrate, has emerged as an important regulator of gene expression andprotein function. Since its discovery in 2019, lactylation has beenincreasingly recognized for its roles in cancer biology and treatment response. Main text: Lactylationis strongly associated with tumor progression and malignancy, underscoring itspotential as a therapeutic target. Recent studies also link lactylation tocancer treatment resistance, suggesting that modulating this modification couldenhance therapeutic efficacy. As treatment resistance remains a major clinicalchallenge in oncology, accumulating evidence indicates that dysregulatedlactylation contributes to resistance across chemotherapy, immunotherapy, targeted therapy, and radiotherapy. Preclinical and clinical research has begunto delineate the molecular pathways through which lactylation shapes theseresistance processes, and experimental approaches targeting lactylation arebeing explored to restore therapeutic sensitivity. Conclusion: This review systematically summarizes the mechanisms of lactylation and its roles intreatment resistance, highlighting the interplay between lactylation andtherapeutic response. We discuss current and emerging strategies that targetlactylation, providing a foundation for future therapeutic development aimed atovercoming resistance and improving cancer treatment outcomes. Key points: Lactylation links glycolysis to tumor progression and therapeutic response. Modulating lactylation writers and erasers restores treatment sensitivity. Aberrant lactylation drives resistance tomultiple cancer therapies. Crosstalk with other post‐translational modifications suggests novel combination strategies.
- Open Access
- 19 August 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-16
Lactylation-mediated miRNA regulation in cancer therapy resistance
Therapeutic resistance in cancer is increasingly understood as a dynamic outcome of the interplay among tumour metabolism, epigenetic regulation, and immune modulation, rather than a consequence of genetic mutations alone. At this intersection, lactylation-a recently discovered lactate-derived post-translational modification (PTM)-acts as a molecular bridge linking metabolic rewiring to transcriptional and post-transcriptional control. Meanwhile, microRNAs (miRNAs) have emerged as essential regulators of metabolic adaptation and epigenetic plasticity. However, the interaction between lactylation and miRNA networks remains largely underexplored. Herein, we present a comprehensive and structured assessment of this emerging interdisciplinary field. We begin with a focused overview of tumour metabolic reprogramming and the enzymology of lactylation, establishing the biochemical context for its regulatory functions. We then examine how miRNAs interpret and reinforce metabolic cues, particularly through three interrelated regulatory frameworks. Lactylation of histones and DNA repair proteins has been shown to activate oncogenic miRNA clusters; these same miRNAs, in turn, enhance glycolytic flux and fine-tune the activity of lactylation enzymes, forming bidirectional feedback loops. Under stress conditions such as hypoxia or chemotherapy, lactate accumulation selectively suppresses DNA-repair-targeting and Pro-apoptotic miRNAs, stabilising BRCA1/RAD51-mediated repair programs. Furthermore, lactylation-dependent miRNA signals disseminate via extracellular vesicles, contributing to T cell exhaustion and macrophage M2 polarisation, thus shaping an immunosuppressive tumour microenvironment. Based on these converging mechanisms, we highlight potential therapeutic strategies, including the co-targeting of LDHA and oncogenic miRNAs (e.g., nanoparticle-mediated delivery of anti-miR-21), as well as liquid biopsy-based monitoring of circulating H3K18la and miRNA signatures to predict emerging resistance. By integrating metabolic, epigenetic, and immunologic perspectives, we position lactylation-miRNA crosstalk as a central regulatory axis in cancer therapy resistance and offer a conceptual framework to inform the development of future mechanism-driven interventions.
- 19 August 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-16
Open AccessLactylation-mediated miRNA regulation in cancer therapy resistance
Therapeutic resistance in cancer is increasingly understood as a dynamic outcome of the interplay among tumour metabolism, epigenetic regulation, and immune modulation, rather than a consequence of genetic mutations alone. At this intersection, lactylation-a recently discovered lactate-derived post-translational modification (PTM)-acts as a molecular bridge linking metabolic rewiring to transcriptional and post-transcriptional control. Meanwhile, microRNAs (miRNAs) have emerged as essential regulators of metabolic adaptation and epigenetic plasticity. However, the interaction between lactylation and miRNA networks remains largely underexplored. Herein, we present a comprehensive and structured assessment of this emerging interdisciplinary field. We begin with a focused overview of tumour metabolic reprogramming and the enzymology of lactylation, establishing the biochemical context for its regulatory functions. We then examine how miRNAs interpret and reinforce metabolic cues, particularly through three interrelated regulatory frameworks. Lactylation of histones and DNA repair proteins has been shown to activate oncogenic miRNA clusters; these same miRNAs, in turn, enhance glycolytic flux and fine-tune the activity of lactylation enzymes, forming bidirectional feedback loops. Under stress conditions such as hypoxia or chemotherapy, lactate accumulation selectively suppresses DNA-repair-targeting and Pro-apoptotic miRNAs, stabilising BRCA1/RAD51-mediated repair programs. Furthermore, lactylation-dependent miRNA signals disseminate via extracellular vesicles, contributing to T cell exhaustion and macrophage M2 polarisation, thus shaping an immunosuppressive tumour microenvironment. Based on these converging mechanisms, we highlight potential therapeutic strategies, including the co-targeting of LDHA and oncogenic miRNAs (e.g., nanoparticle-mediated delivery of anti-miR-21), as well as liquid biopsy-based monitoring of circulating H3K18la and miRNA signatures to predict emerging resistance. By integrating metabolic, epigenetic, and immunologic perspectives, we position lactylation-miRNA crosstalk as a central regulatory axis in cancer therapy resistance and offer a conceptual framework to inform the development of future mechanism-driven interventions.
- Open Access
- 2 July 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-18
The role and therapeutic value of NUSAP1 in human cancers
In recent years, the incidence of cancer has increased, and early diagnosis and treatment are key to cancer treatment. Nucleolar and spindle-associated protein 1 (NUSAP1) is a crucial mitotic regulator. NUSAP1 binds to microtubules and mediates their attachment to chromosomes, ensuring the accurate distribution of genetic material to the two daughter cells. NUSAP1 is located on chromosome 15q15.1 and is typically expressed in proliferating cells, suggesting a potential oncogenic role. Studies have shown that NUSAP1 plays a significant role in various cancers, including breast cancer, cervical cancer, lung cancer, prostate cancer, and hepatocellular carcinoma. Furthermore, NUSAP1 may serve as a promising biomarker for cancer diagnosis and prognosis. In this review, we discuss the roles and mechanisms of NUSAP1 in human cancers.
- 2 July 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-18
Open AccessThe role and therapeutic value of NUSAP1 in human cancers
In recent years, the incidence of cancer has increased, and early diagnosis and treatment are key to cancer treatment. Nucleolar and spindle-associated protein 1 (NUSAP1) is a crucial mitotic regulator. NUSAP1 binds to microtubules and mediates their attachment to chromosomes, ensuring the accurate distribution of genetic material to the two daughter cells. NUSAP1 is located on chromosome 15q15.1 and is typically expressed in proliferating cells, suggesting a potential oncogenic role. Studies have shown that NUSAP1 plays a significant role in various cancers, including breast cancer, cervical cancer, lung cancer, prostate cancer, and hepatocellular carcinoma. Furthermore, NUSAP1 may serve as a promising biomarker for cancer diagnosis and prognosis. In this review, we discuss the roles and mechanisms of NUSAP1 in human cancers.
- Open Access
- 1 July 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 1-15
Urea cycle dysregulation: a new frontier in cancer metabolism and immune evasion
Cancer cells experience metabolic reprogramming to enhance the synthesis of nitrogen and carbon, facilitating the production of macromolecules essential for tumor proliferation and growth. A central strategy in this process involves reducing catabolic activities and managing nitrogen, thereby improving the efficiency of nitrogen utilization. The urea cycle (UC), conventionally recognized for its role in detoxifying excess nitrogen in the liver, is pivotal in this metabolic transition. Beyond the hepatic environment, the differential expression of UC enzymes facilitates the utilization of nitrogen for the synthesis of metabolic intermediates, thereby addressing the cellular metabolic requirements, especially under conditions of nutrient scarcity. In oncogenic contexts, the expression and regulation of UC enzymes undergo substantial modification, promoting metabolic reprogramming to optimize nitrogen assimilation into cellular biomass. This reconfigured UC not only enhances tumor cell survival but also plays a pivotal role in the reorganization of the tumor microenvironment (TME), thereby aiding in immune evasion. This review examines the mechanistic underpinnings of urea cycle dysregulation (UCD) in cancer, highlighting its dynamic roles across various tumor types and stages, as well as the therapeutic implications of these alterations. Understanding how UC relaxation promotes metabolic flexibility and immune evasion may help develop novel therapeutic strategies that target tumor metabolism and enhance anti-cancer immunity.
- 1 July 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 1-15
Open AccessUrea cycle dysregulation: a new frontier in cancer metabolism and immune evasion
Cancer cells experience metabolic reprogramming to enhance the synthesis of nitrogen and carbon, facilitating the production of macromolecules essential for tumor proliferation and growth. A central strategy in this process involves reducing catabolic activities and managing nitrogen, thereby improving the efficiency of nitrogen utilization. The urea cycle (UC), conventionally recognized for its role in detoxifying excess nitrogen in the liver, is pivotal in this metabolic transition. Beyond the hepatic environment, the differential expression of UC enzymes facilitates the utilization of nitrogen for the synthesis of metabolic intermediates, thereby addressing the cellular metabolic requirements, especially under conditions of nutrient scarcity. In oncogenic contexts, the expression and regulation of UC enzymes undergo substantial modification, promoting metabolic reprogramming to optimize nitrogen assimilation into cellular biomass. This reconfigured UC not only enhances tumor cell survival but also plays a pivotal role in the reorganization of the tumor microenvironment (TME), thereby aiding in immune evasion. This review examines the mechanistic underpinnings of urea cycle dysregulation (UCD) in cancer, highlighting its dynamic roles across various tumor types and stages, as well as the therapeutic implications of these alterations. Understanding how UC relaxation promotes metabolic flexibility and immune evasion may help develop novel therapeutic strategies that target tumor metabolism and enhance anti-cancer immunity.
- Open Access
- 10 June 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-16
Branched-chain amino acid and cancer: metabolism, immune microenvironment and therapeutic targets
Cancer is one of the major diseases threatening human health in the world. According to the latest global cancer statistics from the International Agency for Research on Cancer (IARC), there were approximately 20 million new cancer cases and 10 million cancer deaths worldwide. Amidst this global health concern, branched chain amino acids have emerged as key players, playing an important role in the occurrence and development of cancer. In certain malignancies like colorectal cancer, the average level of BCAA in tumor tissues is twice that in normal tissues. BCAA metabolism is intricately associated with the progression of multiple tumors and is modulated by diverse enzymes, including BCAT, BCKDH, and BCKDK. The metabolism of BCAA involves multiple enzymes and biochemical processes via signaling pathways such as PI3K/AKT/mTOR and AMPK/mTOR, etc. In addition, mTOR inhibitors show potential value in cancer treatment by regulating the metabolism and signaling pathways of tumor cells, which provides a new direction for anticancer efforts. Simultaneously, BCAAs are closely associated with tumor immunity, including NK cells, CD4+ T cells, and CD8+ T cells. At present, the research on BCAA metabolism and related enzymes and signaling pathways is still in progress, aiming at identifying new targets and ideas for cancer therapy, and combined therapy will become an important trend in the future. In this review, we discuss the role and mechanisms of BCAA metabolism in human cancer.
- 10 June 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-16
Open AccessBranched-chain amino acid and cancer: metabolism, immune microenvironment and therapeutic targets
Cancer is one of the major diseases threatening human health in the world. According to the latest global cancer statistics from the International Agency for Research on Cancer (IARC), there were approximately 20 million new cancer cases and 10 million cancer deaths worldwide. Amidst this global health concern, branched chain amino acids have emerged as key players, playing an important role in the occurrence and development of cancer. In certain malignancies like colorectal cancer, the average level of BCAA in tumor tissues is twice that in normal tissues. BCAA metabolism is intricately associated with the progression of multiple tumors and is modulated by diverse enzymes, including BCAT, BCKDH, and BCKDK. The metabolism of BCAA involves multiple enzymes and biochemical processes via signaling pathways such as PI3K/AKT/mTOR and AMPK/mTOR, etc. In addition, mTOR inhibitors show potential value in cancer treatment by regulating the metabolism and signaling pathways of tumor cells, which provides a new direction for anticancer efforts. Simultaneously, BCAAs are closely associated with tumor immunity, including NK cells, CD4+ T cells, and CD8+ T cells. At present, the research on BCAA metabolism and related enzymes and signaling pathways is still in progress, aiming at identifying new targets and ideas for cancer therapy, and combined therapy will become an important trend in the future. In this review, we discuss the role and mechanisms of BCAA metabolism in human cancer.
- 14 February 2025
- Published by Elsevier in Cellular Signalling
- Vol. 129, 111655
LZTS3 represses tumorigenesis and radioresistance via CK1δ and β-TrCP-mediated ubiquitination pathway in lung cancer
- 14 February 2025
- Published by Elsevier in Cellular Signalling
- Vol. 129, 111655
LZTS3 represses tumorigenesis and radioresistance via CK1δ and β-TrCP-mediated ubiquitination pathway in lung cancer
- Open Access
- 16 June 2023
- Published by Elsevier in Cellular Signalling
- Vol. 109, 110775
STNM1 in human cancers: role, function and potential therapy sensitizer
- 16 June 2023
- Published by Elsevier in Cellular Signalling
- Vol. 109, 110775
Open AccessSTNM1 in human cancers: role, function and potential therapy sensitizer
- Open Access
- 24 May 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 164, 114929
The roles, molecular interactions, and therapeutic value of CDK16 in human cancers
- 24 May 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 164, 114929
Open AccessThe roles, molecular interactions, and therapeutic value of CDK16 in human cancers
- Open Access
- 1 December 2022
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 20 (1) , 1-6
Breast metastasis of signet ring cell carcinoma from the colon: a case report
Background: Colon cancer is one of the most common diagnosed malignancies. Despite the use of surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, and other comprehensive treatments, distant metastasis is still one of the main causes for dying of colon cancer. The common metastatic site of colon cancer is the liver, lung, and bone. In this article, we report a rare case of breast metastasis of signet ring cell carcinoma from the colon. Case presentation: A 44-year-old woman was diagnosed with colon cancer and received a radical surgery of colon cancer in 2019. Combined with postoperative pathological and computed tomography (CT) images, a diagnosis of cT3N2M0 mucinous adenocarcinoma of colon (according to AJCC cancer staging manual, Version 8) was established. Adjuvant chemotherapy (XELOX: oxaliplatin 130 mg/m2 on day 1 plus capecitabine 1000 mg/m2 twice daily on days 1 to 14 every 3 weeks for 18 weeks) was performed followed by surgical resection. Fourteen months later, the patient underwent mastectomy for breast mass, which was diagnosed pathologically as metastasis of signet ring cell carcinoma from the colon. XELOX chemotherapy regimen (oxaliplatin 130 mg/m2 on day 1 plus capecitabine 1000 mg/m2 twice daily on days 1 to 14 every 3 weeks for 24 weeks) combined with bevacizumab (7.5 mg/kg on day 1) was used after the mastectomy. The patient had stable disease according to her last examination (RECIST criteria). Conclusion: It is rare to find a report of a patient of colon cancer that metastasizes to breast. We hope to increase treatment experience for patients with this rare metastasis.
- 1 December 2022
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 20 (1) , 1-6
Open AccessBreast metastasis of signet ring cell carcinoma from the colon: a case report
Background: Colon cancer is one of the most common diagnosed malignancies. Despite the use of surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, and other comprehensive treatments, distant metastasis is still one of the main causes for dying of colon cancer. The common metastatic site of colon cancer is the liver, lung, and bone. In this article, we report a rare case of breast metastasis of signet ring cell carcinoma from the colon. Case presentation: A 44-year-old woman was diagnosed with colon cancer and received a radical surgery of colon cancer in 2019. Combined with postoperative pathological and computed tomography (CT) images, a diagnosis of cT3N2M0 mucinous adenocarcinoma of colon (according to AJCC cancer staging manual, Version 8) was established. Adjuvant chemotherapy (XELOX: oxaliplatin 130 mg/m2 on day 1 plus capecitabine 1000 mg/m2 twice daily on days 1 to 14 every 3 weeks for 18 weeks) was performed followed by surgical resection. Fourteen months later, the patient underwent mastectomy for breast mass, which was diagnosed pathologically as metastasis of signet ring cell carcinoma from the colon. XELOX chemotherapy regimen (oxaliplatin 130 mg/m2 on day 1 plus capecitabine 1000 mg/m2 twice daily on days 1 to 14 every 3 weeks for 24 weeks) combined with bevacizumab (7.5 mg/kg on day 1) was used after the mastectomy. The patient had stable disease according to her last examination (RECIST criteria). Conclusion: It is rare to find a report of a patient of colon cancer that metastasizes to breast. We hope to increase treatment experience for patients with this rare metastasis.